Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection

Journal of Clinical Microbiology

Volumn 45, Issue 12, 2007, Pages 3942-3947

  Wong, Danny Ka Ho ^a   Tanaka, Yasuhito ^b   Lai, Ching Lung ^a   Mizokami, Masashi ^b   Fung, James ^a   Yuen, Man Fung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; ENTECAVIR; HEPATITIS B CORE ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; VIRUS DNA;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHEMOLUMINESCENCE; CHRONIC HEPATITIS; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; HEPATITIS B; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS REPLICATION;

ADULT; CHEMILUMINESCENT MEASUREMENTS; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GUANINE; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NECROSIS; STATISTICS AS TOPIC;

HEPATITIS B VIRUS;

EID: 37249092014     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00366-07     Document Type: Article

References (20)

1. Bredehorst, R., H. von Wulffen, and C. Granato. 1985. Quantitation of hepatitis B virus (HBV) core antigen in serum in the presence of antibodies to HBV core antigen: comparison with assays of serum HBV DNA, DNA polymerase, and HBV e antigen. J. Clin. Microbiol. 21:593-598.
2. Chang, T. T., R. G. Gish, R. de Man, A. Gadano, J. Sollano, Y. C. Chao, A. S. Lok, K. H. Han, Z. Goodman, J. Zhu, A. Cross, D. DeHertogh, R. Wilber, R. Colonno, and D. Apelian. 2006. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354:1001-1010.
3. Gowans, E. J. 1986. Relationship between HBeAg and HBV DNA in patients with acute and persistent hepatitis B infection. Med. J. Aust. 145:439-441.
4. Kimura, T., N. Ohno, N. Terada, A. Rokuhara, A. Matsumoto, S. Yagi, E. Tanaka, K. Kiyosawa, S. Ohno, and N. Maki. 2005. Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain. J. Biol. Chem. 280:21713-21719.
5. Kimura, T., A. Rokuhara, Y. Sakamoto, S. Yagi, E. Tanaka, K. Kiyosawa, and N. Maki. 2002. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J. Clin. Microbiol. 40:439-445.
6. Knodell, R. G., K. G. Ishak, W. C. Black, T. S. Chen, R. Craig, N. Kaplowitz, T. W. Kiernan, and J. Wollman. 1981. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431-435.
7. Lai, C. L., V. Ratziu, M. F. Yuen, and T. Poynard. 2003. Viral hepatitis B. Lancet 362:2089-2094.
8. Lai, C. L., D. Shouval, A. S. Lok, T. T. Chang, H. Cheinquer, Z. Goodman, D. DeHertogh, R. Wilber, R. C. Zink, A. Cross, R. Colonno, and L. Fernandes. 2006. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354:1011-1020.
9. Marion, P. L., F. H. Salazar, M. A. Winters, and R. J. Colonno. 2002. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob. Agents Chemother. 46:82-88.
10. Matsumoto, A., E. Tanaka, M. Minami, T. Okanoue, H. Yatsuhashi, S. Nagaoka, F. Suzuki, M. Kobayashi, K. Chayama, M. Imamura, H. Yotsuyanagi, S. Nakaoka, N. Maki, S. Kawata, H. Kumada, S. lino, and K. Kiyosawa. 2007. Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy. Hepatol. Res. 37:661-666.
11. Misawa, N., A. Matsumoto, E. Tanaka, A. Rokuhara, K. Yoshizawa, T. Umemura, N. Maki, T. Kimura, and K. Kiyosawa. 2006. Patients with and without loss of hepatitis B virus DNA after hepatitis B e antigen seroconversion have different virological characteristics. J. Med. Virol. 78:68-73.
12. Rokuhara, A., X. Sun, E. Tanaka, T. Kimura, A. Matsumoto, D. Yao, L. Yin, N. Wang, N. Maki, and K. Kiyosawa. 2005. Hepatitis B virus core and core-related antigen quantitation in Chinese patients with chronic genotype B and C hepatitis B virus infection. J. Gastroenterol. Hepatol. 20:1726-1730.
13. Rokuhara, A., E. Tanaka, A. Matsumoto, T. Kimura, T. Yamaura, K. Orii, X. Sun, S. Yagi, N. Maki, and K. Kiyosawa. 2003. Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment. J. Viral Hepat. 10:324-330.
14. Shinkai, N., Y. Tanaka, E. Orito, K. Ito, T. Ohno, N. Hirashima, I. Hasegawa, F. Sugauchi, R. Ueda, and M. Mizokami. 2006. Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection. Hepatol. Res. 36:272-276.
15. Tanaka, E., A. Matsumoto, F. Suzuki, M. Kobayashi, M. Mizokami, Y. Tanaka, T. Okanoue, M. Minami, K. Chayama, M. Imamura, H. Yatsuhashi, S. Nagaoka, H. Yotsuyanagi, S. Kawata, T. Kimura, N. Maki, S. Iino, and K. Kiyosawa. 2006. Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance. Liver Int. 26:90-96.
16. Usuda, S., H. Okamoto, F. Tsuda, T. Tanaka, Y. Miyakawa, and M. Mayumi. 1998. An enzyme-linked immunosorbent assay with monoclonal antibodies for the determination of phosphorylated hepatitis B core protein (p21c) in serum. J. Virol. Methods 72:95-103.
17. Wolters, L. M., B. E. Hansen, H. G. Niesters, S. Zeuzem, S. W. Schalm, and R. A. De Man. 2002. Viral dynamics in chronic hepatitis B patients during lamivudine therapy. Liver 22:121-126.
18. Wong, D. K. H., M. F. Yuen, H. Yuan, S. S. Sum, C. K. Hui, J. Hall, and C. L. Lai. 2004. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 40:727-737.
19. Yuan, H. J., M. F. Yuen, D. K. H. Wong, S. M. Sum, E. Sablon, I. O. L. Ng, and C. L. Lai. 2005. Impact of precore and core promoter mutations on hepatic histology in patients with chronic hepatitis B. Aliment. Pharmacol. Ther. 22:301-307.
20. Yuen, M. F., E. Sablon, C. K. Hui, H. J. Yuan, H. Decraemer, and C. L. Lai. 2001. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34:785-791.